Articles from this edition:
Latest articles
Mind the generation gap in pharma marketing and market research
Industry came together to explore the impact of the generation gap in pharma marketing and market research at BHBIA's summer event. Different generations have always...
AstraZeneca presents anifrolumab results from Phase III TULIP trial
Results from the positive Phase III TULIP 2 trial for AstraZeneca's anifrolumab, a potential new medicine for the treatment of moderate to severe systemic...
Novartis advanced breast cancer treatment approved in Scotland
Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...
Popular articles
Novartis advanced breast cancer treatment approved in Scotland
Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...
Myth busting remote sales solutions
Peter Hyde, Managing Director at Alveo Solutions, looks at the common myths and deciphers the reality of remote sales solutions. The industry is increasingly adopting remote...
Mapping NHS change is key to customer engagement
Simon Grime, of Wilmington Healthcare, explains how mapping NHS change through data and intelligence can help industry understand and engage customers in the new...
AstraZeneca presents anifrolumab results from Phase III TULIP trial
Results from the positive Phase III TULIP 2 trial for AstraZeneca's anifrolumab, a potential new medicine for the treatment of moderate to severe systemic...
AstraZeneca to appeal NICE’s osimertinib decision
AstraZeneca to appeal NICE's osimertinib decision following it not being recommended for use within NHS England. AstraZeneca will appeal a decision by the National Institute...